-
公开(公告)号：US20080280933A1
公开(公告)日：2008-11-13
申请号：US11780579
申请日：2007-07-20
申请人： Ivan Efremov , Bruce N. Rogers , Allen J. Duplantier , Lei Zhang , Qian Zhang , Noha S. Maklad , Edelweiss Evrard , Michael A. Brodney
发明人： Ivan Efremov , Bruce N. Rogers , Allen J. Duplantier , Lei Zhang , Qian Zhang , Noha S. Maklad , Edelweiss Evrard , Michael A. Brodney
IPC分类号： C07D401/02 , A61K31/454 , A61K31/438 , C07D487/10 , A61P25/00
CPC分类号： C07D401/06 , C07D405/14 , C07D413/14 , C07D471/10 , C07D491/052 , C07D491/107
摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
摘要翻译： 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US07795447B2
公开(公告)日：2010-09-14
申请号：US11971272
申请日：2008-01-09
IPC分类号： A61K31/4164 , C07D233/88
CPC分类号： C07D233/88 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D471/04 , C07D487/04
摘要： The present invention relates to compounds of the Formula I wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
摘要翻译： 本发明涉及式Ⅰ化合物，其中R1，R2，R3，R4，R6，R7和A定义如上。 式I的化合物具有抑制Aβ产生的活性。 本发明还涉及用于治疗疾病和病症的药物组合物和方法，例如包含式I化合物的哺乳动物的神经变性和/或神经障碍，例如阿尔茨海默病。
-
公开(公告)号：US07345038B2
公开(公告)日：2008-03-18
申请号：US10800328
申请日：2004-03-12
CPC分类号： C07D471/04
摘要： An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound of formula I, pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression, wherein formula I is or a pharmaceutically acceptable salt or thereof, wherein Z is wherein Y is methylene; X is oxygen; n is 0; R1 and R2 are each hydrogen or halogen; and R3 and R4 together with the nitrogen atom to which they are attached form i) a saturated non-aromatic 3 to 7 membered monocyclic ring, said ring i) being unsubstituted or substituted or substituted with one or more (C1–C4)alkyl, (C1–C4)alkoxy(C1–C4)alkyl, or hydroxy groups.
摘要翻译： 式I的氨基甲基吡啶氧基甲基/苯并异恶唑取代的氮杂双环化合物，包含其的药物组合物和治疗一种或多种CNS或其它病症的方法，包括同时治疗诸如精神分裂症和抑郁症的病症，其中式I是或其药学上可接受的盐或 其中Z是其中Y是亚甲基; X是氧; n为0; R 1和R 2各自为氢或卤素; 和R 3和R 4与它们所连接的氮原子一起形成i）饱和的非芳香族3至7元单环，所述环i）为 未取代或取代或被一个或多个（C 1 -C 4 -C 4）烷基取代的（C 1 -C 4 - 或烷氧基（C 1 -C 4 -C 4烷基）或羟基。
-
4.发明申请Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases 审中-公开新型螺旋哌嗪类治疗神经退行性疾病公开(公告)号：US20110046160A1
公开(公告)日：2011-02-24
申请号：US12990739
申请日：2009-05-04
IPC分类号： A61K31/497 , C07D513/10 , A61K31/438 , A61K31/506 , A61P25/28
CPC分类号： C07D513/10
摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
摘要翻译： 公开了化合物的化合物和药学上可接受的盐，其中所述化合物具有如说明书中定义的式（I）的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US07781435B2
公开(公告)日：2010-08-24
申请号：US11524425
申请日：2006-09-20
申请人： Michael A. Brodney , Karen J. Coffman , Edward F. Kleinman , Brian T. O'Neill , Yuhpyng L. Chen
发明人： Michael A. Brodney , Karen J. Coffman , Edward F. Kleinman , Brian T. O'Neill , Yuhpyng L. Chen
IPC分类号： A61K31/5377 , A61K31/454 , A61K31/4178 , A61K31/4172 , C07D413/02 , C07D405/02 , C07D403/02
CPC分类号： C07D233/88 , C07D233/54 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/10 , C07D403/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/06 , C07D413/12 , C07D451/02 , C07D487/04 , C07D487/08 , C07D491/04
摘要： The present invention relates to compounds of Formula I wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of Formula I.
摘要翻译： 本发明涉及式Ⅰ化合物，其中R 1，R 2，R 3，R 4，R 6，R 7和A如上所定义。 式I的化合物具有抑制Aβ产生的活性。 本发明还涉及用于治疗疾病和病症的药物组合物和方法，例如包含式I化合物的哺乳动物的神经变性和/或神经障碍，例如阿尔茨海默氏病。
-
公开(公告)号：US07342118B2
公开(公告)日：2008-03-11
申请号：US11078898
申请日：2005-03-11
IPC分类号： A61K31/4164 , A61K31/4178 , C07D403/06 , C07D233/88
CPC分类号： C07D233/88 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D471/04 , C07D487/04
摘要： The present invention relates to compounds of the Formula I wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
摘要翻译： 本发明涉及式I化合物，其中R 1，R 2，R 3，R 4， R 6，R 7和A如上所定义。 式I的化合物具有抑制Abeta肽生产的活性。 本发明还涉及用于治疗疾病和病症的药物组合物和方法，例如包含式I化合物的哺乳动物的神经变性和/或神经障碍，例如阿尔茨海默病。
-
公开(公告)号：US20100292205A1
公开(公告)日：2010-11-18
申请号：US12438198
申请日：2007-08-13
申请人： Bruce A. Lefker , Michael A. Brodney , Subas M. Sakya , Bruce A. Hay , Matthew D. Wessel , Edward L. Conn
发明人： Bruce A. Lefker , Michael A. Brodney , Subas M. Sakya , Bruce A. Hay , Matthew D. Wessel , Edward L. Conn
IPC分类号： A61K31/397 , C07D401/14 , C07D401/04 , C07D403/14 , C07D487/04 , A61P35/00 , A61P29/00 , A61P25/28 , A61P9/10 , A61P9/00 , A61P21/00 , A61P3/04 , A61P43/00 , A61P25/00 , A61K31/513 , A61K31/4985 , A61K31/55 , A61K31/5025 , A61K31/519 , A61K31/53
CPC分类号： C07D401/14 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04
摘要： The invention pertains to pyrimidone compounds that serve as effective GSK-3 inhibitors. The invention further relates to pharmaceutical compositions and methods comprising such pyrimidone compounds; and the use of such compounds for treating certain disorders.
摘要翻译： 本发明涉及用作有效GSK-3抑制剂的嘧啶酮化合物。 本发明还涉及包含这种嘧啶酮化合物的药物组合物和方法; 以及这些化合物用于治疗某些疾病的用途。
-
公开(公告)号：US07345095B2
公开(公告)日：2008-03-18
申请号：US11539219
申请日：2006-10-06
IPC分类号： A61K31/18
CPC分类号： C07C311/19 , C07C311/29 , C07C323/49 , C07C2602/10 , C07D215/233 , C07D257/04 , C07D271/06 , C07D295/135
摘要： The present invention relates to compounds of the Formula I wherein R1, R2, R3, m, and n are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
摘要翻译： 本发明涉及式Ⅰ化合物，其中R 1，R 2，R 3，m和n如上定义。 式I的化合物具有抑制Abeta肽生产的活性。 本发明还涉及用于治疗疾病和疾病的药物组合物和方法，例如包含式I化合物的哺乳动物中的神经变性和/或神经障碍，例如阿尔茨海默病。
-
公开(公告)号：US07163942B2
公开(公告)日：2007-01-16
申请号：US11078739
申请日：2005-03-11
IPC分类号： A61K31/18 , C07C311/20 , C07C311/21
CPC分类号： C07C311/19 , C07C311/29 , C07C323/49 , C07C2602/10 , C07D215/233 , C07D257/04 , C07D271/06 , C07D295/135
摘要： The present invention relates to compounds of the Formula I wherein R1, R2, R3, m, and n are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
摘要翻译： 本发明涉及式Ⅰ化合物，其中R 1，R 2，R 3，m和n如上定义。 式I的化合物具有抑制Abeta肽生产的活性。 本发明还涉及用于治疗疾病和疾病的药物组合物和方法，例如包含式I化合物的哺乳动物中的神经变性和/或神经障碍，例如阿尔茨海默病。
-
公开(公告)号：US20110224231A1
公开(公告)日：2011-09-15
申请号：US13130192
申请日：2009-11-12
IPC分类号： A61K31/4965 , C07D471/10 , A61K31/438 , A61P25/00 , A61P25/18
CPC分类号： C07D471/10
摘要： Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment methods of synthesis, and intermediates are also disclosed.
摘要翻译： 公开了化合物的化合物和药学上可接受的盐，其中所述化合物具有如说明书中定义的式（I）的结构。 还公开了相应的药物组合物，合成方法和中间体的方法。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.037 秒)
